

S



FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer



Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

PE For, 9 May 2002

GlaxoSmithKline plc  
(Name of registrant)

GLAXOSMITHKLINE, 980 GREAT WEST ROAD,  
BRENTFORD, MIDDLESEX TW8 9GS  
(Address of principal executive offices)

PROCESSED  
MAY 20 2002  
THOMSON  
FINANCIAL

Indicated by check mark whether the registrant files or will file annual reports  
under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information  
contained in this Form is also thereby furnishing the information to the  
Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes  No



**GlaxoSmithKline plc**  
980 Great West Road  
Brentford  
Middlesex  
TW8 9GS  
Tel. +44 (0)20 8047 5000  
[www.gsk.com](http://www.gsk.com)

### **Directors' Interests**

I give below details of changes in directors' interests in the Ordinary Shares of GlaxoSmithKline plc.

8 May 2002                      Abacus (GW) Trustees Limited, as trustee of The Glaxo Wellcome Employee Trust ("the Trust"), transferred 7,483 Ordinary Shares in the Company to participants of the GlaxoSmithKline Performance Share Plan and the Glaxo Wellcome 1999 Long Term Incentive Plan. The Trust also sold 753 Ordinary Shares in the Company at £16.3525 per share.

The Company was advised of these transactions on 9 May 2002.

The Trust is a discretionary trust of which all employees or former employees of GlaxoSmithKline Services Unlimited (formerly Glaxo Wellcome plc) and its subsidiaries are potential beneficiaries. Two of the Company's directors, Sir Richard Sykes and John Coombe are therefore interested in the shares held in the Trust from time to time in the same way as other employees or former employees of GlaxoSmithKline Services Unlimited and its subsidiaries.

S M Bicknell  
Company Secretary


9 May 2002

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: 9 May, 2002

By:   
LORRAINE DAY  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc